Authors concluded that HSP90 inhibitors may be a good target in some cases, though, combination with chemotherapeutic agents and histone deacetylase (HDAC) inhibitors may be used to improve anti-tumor activity (122). Here, HSP90AB1 is linked to neoplasm.